Last reviewed · How we verify
BIA 5-453
At a glance
| Generic name | BIA 5-453 |
|---|---|
| Also known as | Etamicastat |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453 (PHASE1)
- Pharmacokinetics of BIA 5-453 and Its Metabolites (PHASE1)
- Bioavailability Study of BIA 5-453 (PHASE1)
- Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites (PHASE1)
- Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453 (PHASE1)
- Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIA 5-453 CI brief — competitive landscape report
- BIA 5-453 updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI